Kintor Pharmaceutical Limited



简体

繁体

搜索

PREV 

NEXT 

About Us

Kintor Pharmaceuticals focuses on developing drugs for androgen-receptor-related diseases with significant unmet medical needs，

including prostate cancer, breast cancer, liver cancer, COVID-19, alopecia, acne, and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Small-molecule drugs

Kintor Pharmaceuticals product pipeline initially focused on androgen receptor (AR) antagonists. Our expanded pipeline now includes mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents, and cMyc inhibitors.

Innovative biologics

Kintor Pharmaceuticals' first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers.

Combination therapies

To provide the best treatment for prostate, breast, and liver cancers and other diseases, Kintor Pharmaceuticals is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a multidisciplinary team of drug developers.

Manufacturing Base

Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing base in Suzhou.

Commercial Operation

In anticipation of the commercial launch of our products, Kintor Pharmaceuticals is building an independent commercialization team. [entity?]

R&D Platform

We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2021-11-24

Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia Patients

Suzhou, November 24, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma, for the treatment of male androgenetic alopecia (“AGA”) patients was cleared by the National Medical Products Administration (“NMPA”). KX-826 is the first androgen receptor (AR) antagonist which has entered the phase III clinical trial for AGA treatment in China and global.

2021-11-12

Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China

Suzhou, November 12, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical trial of pyrilutamide ("KX-826") in China for the treatment of androgenetic alopecia (AGA) female patients.

2021-11-09

Indonesian Ambassador to China and the Delegation Visited Kintor

In the afternoon of November 8, 2021, Indonesian Ambassador to China, H.E. Djauhari Oratmangun, Indonesian Consul General in Shanghai, Mr. Deny Wachyudi Kurnia, and the Chairman of the Indonesia Chamber of Commercein China, Mr. Liky Sutikno, visited Kintor Pharma for in-depth understanding of the company. The delegation met with founder, Chairman and CEO, Dr. Youzhi Tong and Kintor Pharma’s executives.